Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,975 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma.
Wesson W, Dima D, Suleman N, Saif MSI, Tabak C, Logan E, Davis JA, McGann M, Furqan F, Mohan M, Rashid A, Abdallah AO, Ullah F, Shune L, Mushtaq MU, Raza S, McGuirk J, Hamadani M, Anwer F, Hashmi H, Ahmed N. Wesson W, et al. Among authors: rashid a. Transplant Cell Ther. 2024 Sep;30(9):876-884. doi: 10.1016/j.jtct.2024.06.012. Epub 2024 Jun 11. Transplant Cell Ther. 2024. PMID: 38871056 Free article.
Safety and efficacy of eltrombopag in patients with post-CAR T cytopenias.
Wesson W, Ahmed N, Rashid A, Tabak C, Logan E, Marchena-Burgos J, Nelson M, Davis JA, McGann M, Shune L, Hoffmann M, Abdallah AO, Hashmi H. Wesson W, et al. Among authors: rashid a. Eur J Haematol. 2024 Apr;112(4):538-546. doi: 10.1111/ejh.14141. Epub 2023 Dec 3. Eur J Haematol. 2024. PMID: 38044594
Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre study.
Dima D, Rashid A, Davis JA, Shune L, Abdallah AO, Li H, DeJarnette S, Khouri J, Williams L, Hashmi H, Raza S, McGuirk J, Anwer F, Ahmed N. Dima D, et al. Among authors: rashid a. Br J Haematol. 2024 Apr;204(4):1293-1299. doi: 10.1111/bjh.19302. Epub 2024 Jan 23. Br J Haematol. 2024. PMID: 38263627
Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy.
Dima D, Abdallah AO, Davis JA, Awada H, Goel U, Rashid A, DeJarnette S, Anwer F, Shune L, Raza S, Mahmoudjafari Z, Williams L, Faiman B, McGuirk JP, Sauter CS, Ahmed N, Khouri J, Hashmi H. Dima D, et al. Among authors: rashid a. Blood Cancer J. 2024 May 31;14(1):90. doi: 10.1038/s41408-024-01068-w. Blood Cancer J. 2024. PMID: 38821914 Free PMC article.
Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy.
Dima D, Goel U, Sannareddy A, Ibeh N, Ullah F, Afrough A, Mazzoni S, Mehdi A, Rudoni J, Raza S, De Simone N, Williams L, Khan A, Rashid A, Rice M, Ricci K, Samaras C, Valent J, Anderson LD Jr, Anwer F, Kaur G, Khouri J. Dima D, et al. Among authors: rashid a. Hematol Oncol. 2024 Jul;42(4):e3293. doi: 10.1002/hon.3293. Hematol Oncol. 2024. PMID: 38872511
Lung function and onset of cardiometabolic diseases in the longitudinal Burden of Obstructive Lung Disease study.
Janson C, Potts J, Malinovschi A, Agarwal D, Ahmed R, Aquart-Stewart A, Harrabi I, Denguezli M, Devereux G, Erhabor GE, Gislason T, Jogi R, Juvekar SK, Knox-Brown B, Koul P, Mortimer K, Nafees AA, Nielsen R, Mahesh PA, Paraguas SNM, Rotevatn AØ, Sooronbaev T, Burney PGJ, Amaral AFS; BOLD Collaborative Research Group. Janson C, et al. BMJ Open Respir Res. 2025 Jan 19;12(1):e002442. doi: 10.1136/bmjresp-2024-002442. BMJ Open Respir Res. 2025. PMID: 39832891 Free article.
1,975 results